Bolt Biotherapeutics provides update on co-development collaboration with Toray

Bolt Biotherapeutics (BOLT) announced that the target of their worldwide co-development collaboration with Toray Industries is Caprin-1, a cancer target discovered by Toray. The collaborators are developing a Boltbody Immune-Stimulating Antibody Conjugate targeting Caprin-1, which is applicable to multiple solid tumor types. Under the existing joint development and license agreement, Toray supplies its proprietary antibodies targeting Caprin-1, such as the antibody TRK-950, and Bolt contributes proprietary linker-payloads from its Boltbody ISAC platform technology. Bolt plans to co-develop and jointly commercialize the resulting ISAC product candidate with Toray.